- Recommendation ID
- NG49/4
- Question
Probiotic and prebiotic supplements:- What is the clinical and cost effectiveness of probiotics or prebiotics to treat NAFLD in adults, young people and children?
- Any explanatory notes
(if applicable) Why this is important:- NAFLD is the most common metabolic liver disease, occurring in approximately 30% of all adults, around 46% of obese people and around 53% of people with type 2 diabetes. Liver fat accumulation is the first stage of more serious chronic liver disease in NAFLD. A small body of evidence supports the use of probiotics in NAFLD but the data are inconclusive and high-quality double-blind randomised placebo-controlled trials are needed. The evidence from cross-sectional studies suggests associations between unfavourable disturbance in gut microbiota and obesity or type 2 diabetes, but there is very limited evidence on whether modifying the gut microbiota influences NAFLD.
Source guidance details
- Comes from guidance
- Non-alcoholic fatty liver disease (NAFLD): assessment and management
- Number
- NG49
- Date issued
- July 2016
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/07/2016 |